Fmr LLC Buys 1,282,469 Shares of Moderna, Inc. (NASDAQ:MRNA)

FMR LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,664,634 shares of the company's stock after purchasing an additional 1,282,469 shares during the quarter. FMR LLC owned about 4.85% of Moderna worth $776,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in MRNA. Wilmington Savings Fund Society FSB lifted its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new stake in shares of Moderna in the 4th quarter valued at $37,000. Venturi Wealth Management LLC lifted its position in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new position in Moderna during the fourth quarter worth $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares during the period. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MRNA shares. Berenberg Bank increased their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and cut their price target for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Argus downgraded Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $58.70.

Remove Ads

Moderna Trading Up 6.9 %

Shares of MRNA traded up $1.70 on Friday, reaching $26.20. 10,999,018 shares of the company's stock traded hands, compared to its average volume of 7,181,061. The stock's 50 day simple moving average is $31.56 and its two-hundred day simple moving average is $41.01. The stock has a market cap of $10.13 billion, a PE ratio of -2.82 and a beta of 2.23. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.